QIAGEN launches novel NGS workflow for simultaneous DNA and RNA analysis for use in cancer profiling at 2019 AMP Annual Meeting
Nov 06 2019

QIAGEN launches novel NGS workflow for simultaneous DNA and RNA analysis for use in cancer profiling at 2019 AMP Annual Meeting

  • QIAseq® Multimodal Panels streamline simultaneous DNA and RNA sequencing for comprehensive solid and liquid tumor profiling
  • Only solution to extract, enrich and sequence DNA variants and RNA fusions and assess gene expression in a single workflow from a single sample within a single day
  • QIAGEN to highlight extensive Sample to Insight portfolio for clinical laboratories at the Association for Molecular Pathology (AMP) Annual Meeting


Hilden, Germany, and Germantown, Maryland, November 6, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using next-generation sequencing (NGS) technologies.

The new QIAseq® Multimodal Panels are the only solution to offer a consolidated workflow to simultaneously detect DNA variants, RNA fusions and gene expression levels from a single sample, with an input as low as 10 ng of total nucleic acid. This unmatched low-input solution reduces a typical 2-3 day workflow to approximately only nine hours by eliminating the need for two separate time-consuming, inefficient and costly workflows for library preparation from separate DNA and RNA samples. Both libraries are generated from the same sample input, sample utilization and, in turn, sampling-induced bias is also reduced. This enables labs to conserve samples of limited availability for further downstream applications.

The new QIAseq products will be showcased this week together with QIAGEN’s full range of Sample to Insight solutions for molecular oncology research and diagnostics at the Association for Molecular Pathology (AMP) 2019 Annual Meeting in Baltimore, Maryland.

“Our new QIAseq Multimodal Panels offer a first-to-market solution that delivers a comprehensive genomic and transcriptomic profiling solution. Our ambition has been to make next-generation sequencing of DNA and RNA faster and easier for laboratories around the world while lowering overall cost,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area and Interim CEO of QIAGEN. “Given our portfolio supporting customers from the Life Sciences to Molecular Diagnostics, QIAGEN is determined to remain at the cutting edge of molecular biology and support the transformation of breakthroughs into benefits for patients and society that help improve outcomes.”

Dr. Vincent Funari, Vice President of Research and Development at NeoGenomics Laboratories, a leading cancer research laboratory and early-access customer of QIAseq Multimodal said: “We leveraged the new QIAseq Multimodal Panels, a cutting-edge method that allowed us to simultaneously identify DNA variants and RNA fusions, for comprehensive profiling of tumors. This new combined solution enabled us to gain additional insight from the same sample without a major increase in turn-around time. Having both genomic and transcript-level information allowed our laboratory to derive integrated insights while streamlining our implementation, scaling up the analysis to address new needs, saving staff time compared to the of running separate sequencing workflows.”

QIAseq Multimodal Panels for DNA and RNA sequencing

Recent advances in NGS and bioinformatics have empowered users to efficiently interrogate DNA and RNA modifications in biological samples, but current approaches require two separate workflows for library preparation – one each for DNA and RNA. Larger sample amounts are needed to generate adequate DNA and RNA for separate library preparation and sequencing, and the process involves long turn-around times and added complexity.

The new QIAseq Multimodal Panels offer a consolidated workflow to simultaneously enrich DNA variants, RNA fusions and gene expression levels from a single sample, with input as low as 10 ng of total nucleic acid. Laboratories will be able to interrogate samples for a range of nucleic acid biomarkers, such as SNVs, CNVs, InDels, RNA fusions, exon skipping events and gene expression levels. This capability can be extended to key applications such as TMB and MSI profiling, supporting a key need in oncology research for integrated and comprehensive profiling of tumor-derived total nucleic acids. The new Sample to Insight workflow is 50% faster than any other current method and includes DNA and RNA bioinformatic analysis and interpretation using QIAGEN’s CLC Genomics Workbench and QIAGEN Clinical Insight Interpret for QIAseq, respectively. Custom panels are supported through GeneGlobe and QIAGEN’s Enterprise Genomic Services, enabling flexible options that address the evolving needs of various laboratories. Translational and clinical researchers can save time with a single-day workflow and maximize the information they derive from valuable biological samples, even from low-yield and poor-quality samples.

For additional information on the QIAseq Multimodal Panels please visit 

QIAGEN’s presence at AMP 2019 (November 6-9, 2019, in Baltimore, Maryland)

At this year’s AMP annual meeting,more than 45 scientific abstracts will feature solutions from QIAGEN’s broad portfolio of molecular testing solutions. QIAGEN will demonstrate novel Sample to Insight solutions, including research solutions such as the QIAseq Multimodal Panels and diagnostic solutions such as the QIAstat-Dx and NeuMoDx PCR systems, and meet with AMP attendees in Booth #3113.

On Wednesday November 6, QIAGEN will present five corporate-sponsored workshops in Room 316-317:

  • 10:00-10:50 a.m. – “Syndromic Solutions to Aid Therapeutic Decision Making for Patients with Respiratory Infection”
  • 1:00-1:50 p.m. – “Lab Experience – Performance Evaluation of QIAGEN’s GeneReader NGS System Workflow in Testing Complex Myeloid and Lung Cancer Samples
  • 2:00-2:50 p.m. – “Reducing Time for Clinical NGS Test Interpretation by 85%
  • 3:00-3:50 p.m. – “The Power of One: Simultaneous DNA Variant Profiling and RNA Fusion Detection in One Sample to Insight Workflow”
  • 4:00-4:50 p.m. – “Reagent Development at Commercial PCR Kit Provider and Cooperations Opportunities for Industry and OEM Partners

For more information about QIAGEN’s presence at AMP 2019, please visit amp.qiagen.com.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Share this page